http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 11:13:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Anika+Therapeutics%2C+Inc.+++++++++++++/26581189.html si-local-file:///var/storage/secattach/20260601/26581189.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Anika+Therapeutics%2C+Inc.+++++++++++++/26581189.html Mon, 01 Jun 2026 11:13:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Anika+Therapeutics%2C+Inc.+++++++++++++/26581189.html si-local-file:///var/storage/secattach/20260601/26581189.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Anika+Therapeutics%2C+Inc.+++++++++++++/26581189.html Mon, 01 Jun 2026 11:13:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+May+01++Filed+by%3A+HENNEMAN+JOHN+B+III/26421804.html si-local-file:///var/storage/secattach/20260504/26421804.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+May+01++Filed+by%3A+HENNEMAN+JOHN+B+III/26421804.html Mon, 04 May 2026 08:34:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+May+01++Filed+by%3A+HENNEMAN+JOHN+B+III/26421804.html si-local-file:///var/storage/secattach/20260504/26421804.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+May+01++Filed+by%3A+HENNEMAN+JOHN+B+III/26421804.html Mon, 04 May 2026 08:34:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Apr+30++Filed+by%3A+Griffin+Stephen+D./26410278.html si-local-file:///var/storage/secattach/20260430/26410278.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Apr+30++Filed+by%3A+Griffin+Stephen+D./26410278.html Thu, 30 Apr 2026 17:23:00 -0400 ANIK O.00173818 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Apr+30++Filed+by%3A+Griffin+Stephen+D./26410278.html si-local-file:///var/storage/secattach/20260430/26410278.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Anika+Therapeutics%2C+Inc.++For%3A+Apr+30++Filed+by%3A+Griffin+Stephen+D./26410278.html Thu, 30 Apr 2026 17:23:00 -0400 ANIK O.00173818 http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html <p align="left">MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence.</p> <p>In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual Meeting of Stockholders on June 9, 2026 (the “2026 Annual Meeting”), to make room for four new highly accomplished executives with deep expertise in medtech commercialization, financial http://www.streetinsider.com/Press+Releases/TELA+Bio+Announces+Strategic+Board+Refreshment+with+Four+Highly+Experienced+Commerical+Leaders+to+Accelerate+Growth+and+Drive+Path+to+Profitability%3B+The+Company+Also+Reports+Preliminary+First+Quarter+/26409359.html Thu, 30 Apr 2026 16:43:00 -0400 A.03854270 A.06372891 A.07275829 A.08164575 A.08377063 A.08423586 A.11399736 A.11608963 A.14067231 A.16852497 A.20009571 A.22499170 A.32289834 A.33634610 A.33902756 A.35454529 A.50203584 ANIK AXGN BVS ELUT MDXG O.00026248 O.00028494 O.00092737 O.00173818 O.01163638 O.02760651 O.04701423 O.04848105 O.05010326 O.05016941 O.06574964 O.07126568 O.08234601 O.15817314 O.18720149 O.19903583 O.20976440 O.24070172 O.25928637 O.29996804 O.30836334 O.31701438 O.59913331 TELA